PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 eukaryotic translation initiation factor 4E Mus musculus 119-162 15601771-4 2004 Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 30-35 15601771-4 2004 Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 132-137 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 eukaryotic translation initiation factor 4E Mus musculus 164-169 34919946-7 2022 In addition, our ChIP results shown that ribavirin inhibited CARM1 which in turn decreased the H3R17me2a, binds to the eukaryotic translation initiation factor 4E (eIF4E) and VEGF promoter region, and reduced the relative mRNA expression level of eIF4E and VEGF in HCC cells. Ribavirin 41-50 eukaryotic translation initiation factor 4E Mus musculus 247-252 31000196-0 2019 Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 121-126 33577917-5 2021 Mechanistically, Ribavirin treatment significantly reduced PRMT5 and eIF4E protein levels and the accumulation of symmetric dimethylation of histone 3 at arginine 8 (H3R8me2s) and that of histone 4 at arginine 3 (H4R3me2s). Ribavirin 17-26 eukaryotic translation initiation factor 4E Mus musculus 69-74 33577917-6 2021 Importantly, inhibition of PRMT5 by ribavirin resulted in promoted H3R8 methylation in eIF4E promoter region. Ribavirin 36-45 eukaryotic translation initiation factor 4E Mus musculus 87-92 31000196-7 2019 Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 43-48 31000196-7 2019 Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. Ribavirin 96-105 eukaryotic translation initiation factor 4E Mus musculus 87-92 31000196-7 2019 Ribavirin acts on NPC cells via inhibiting eIF4E/Akt signaling, and the suppression of eIF4E by ribavirin are not the consequence of inhibition of eIF4E upstream signaling: Mnk and mTOR. Ribavirin 96-105 eukaryotic translation initiation factor 4E Mus musculus 87-92 31000196-2 2019 In this work, we demonstrate that eIF4E inhibition using both ribavirin and siRNA targets NPC cells and enhances the efficacy of 5-fluorouracil (5-FU). Ribavirin 62-71 eukaryotic translation initiation factor 4E Mus musculus 34-39 28864377-0 2017 Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-beta-Catenin Axis. Ribavirin 15-24 eukaryotic translation initiation factor 4E Mus musculus 72-77 30929914-6 2019 We identify eIF4E as a therapeutically actionable targets by showing that ribavirin, an anti-viral drug, phenocopies the effects of eIF4E knockdown in NPC. Ribavirin 74-83 eukaryotic translation initiation factor 4E Mus musculus 12-17 30929914-6 2019 We identify eIF4E as a therapeutically actionable targets by showing that ribavirin, an anti-viral drug, phenocopies the effects of eIF4E knockdown in NPC. Ribavirin 74-83 eukaryotic translation initiation factor 4E Mus musculus 132-137 30929914-7 2019 We further demonstrate that ribavirin acts on chemoresistant NPC cells through suppressing eIF4E activity and oncogenic protein translation. Ribavirin 28-37 eukaryotic translation initiation factor 4E Mus musculus 91-96 28864377-2 2017 Ribavirin, an anti-viral drug, has been identified as an eIF4E inhibitor. Ribavirin 0-9 eukaryotic translation initiation factor 4E Mus musculus 57-62 28864377-9 2017 Mechanistically, ribavirin suppressed eIF4E phosphorylation and overexpression of its wildtype and phosphor-mimetic form (S209D) but not of the non-phosphorylatable form (S209A), which rescued the inhibitory effects of ribavirin in thyroid cancer cells. Ribavirin 17-26 eukaryotic translation initiation factor 4E Mus musculus 38-43 28864377-13 2017 The in vivo inhibitory effects of ribavirin on phosphorylation of eIF4E and beta-catenin were also observed in thyroid tumor. Ribavirin 34-43 eukaryotic translation initiation factor 4E Mus musculus 66-71 28864377-14 2017 CONCLUSIONS: Our data clearly demonstrate that ribavirin acts on thyroid cancer cells by inhibiting eIF4E/beta-catenin signaling. Ribavirin 47-56 eukaryotic translation initiation factor 4E Mus musculus 100-105 28864377-15 2017 Our findings suggest that ribavirin has the potential to be repurposed for thyroid cancer treatment and also highlight the therapeutic value of inhibiting eIF4E-beta-catenin in thyroid cancer. Ribavirin 26-35 eukaryotic translation initiation factor 4E Mus musculus 155-160